(IMMU) |
| 0 (0%) 11-21 16:45 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 9.64 |
| Resistance 1: | 9.37 |
| Pivot price: | 9.33 |
| Support 1: | 8.93 |
| Support 2: | 7.43 |
| 52w High: | |
| 52w Low: |
| EPS | 0.950 |
| Book Value | 10.980 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.711 |
| Profit Margin (%) | 134.48 |
| Operating Margin (%) | 78.28 |
| Return on Assets (ttm) | 2.1 |
| Return on Equity (ttm) | 8.8 |
Thu, 12 Nov 2026
We Think Mendus (STO:IMMU) Needs To Drive Business Growth Carefully - Simply Wall St
Wed, 11 Nov 2026
IMMU: Clinical programs advanced, but efficacy readouts remain ahead; cash runway extends into Q2 2027 - TradingView
Wed, 11 Nov 2026
IMMU: VITAL-CML cleared safety, with key AML and CML readouts due through 2027 - TradingView
Tue, 10 Nov 2026
Mendus AB (publ) (IMMU) Reports Positive VITAL-CML Safety Review - TradingView
Fri, 14 Jan 2022
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy - Vanderbilt Health News
Wed, 20 Feb 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer - NEJM
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |